The upregulation of these molecules does sensitize ALL to cytolysis, but one must include in the analysis of CAR-T activity the strong induction of NK-like and CTAK killing activity, above and beyond CD22 antigen upregulation. The gene discussed is CD22; the disease is acute lymphoblastic leukemia.